Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg
Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, the generic version of Cardene®1 Capsules, 20 mg and 30 mg,
Glenmark Pharmaceuticals Limited (Glenmark) has received final
approval by the United States Food & Drug Administration (U.S. FDA) for Nicardipine Hydrochloride
Capsules, 20 mg and 30 mg, the generic version of Cardene®1
Capsules, 20 mg and 30 mg, of Chiesi
USA, Inc. Glenmark’s Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, will be distributed in the
U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIATM sales data for the 12-month period ending October 2022, the Cardene® Capsules,
20 mg and 30 mg market2
achieved annual sales of approximately $10.9 million*.
Glenmark’s current portfolio consists of 178 products authorized for distribution in the U.S.
marketplace and 46 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and
accelerate the growth of its existing pipeline and portfolio.
